Finance

Lists
Why is LABB up 2.11%?
Dive Deeper
LABB:BMV
Genomma Lab Internacional SAB de CV
MX$13.06
+2.11%
(+0.27) 1D
Oct 9, 2:00:00 PM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for LABB...
Open
MX$12.85
High
MX$13.10
Low
MX$12.76
Mkt. cap
13.04B
Avg. vol.
3.90M
Volume
4.31M
Dividend
5.74%
Quarterly dividend
MX$0.19
Ex-dividend date
Sep 29, 2026
P/E ratio
7.85
52-wk high
MX$19.48
52-wk low
MX$12.22
EPS
MX$1.66
Shares outstanding
1.00B
No. of employees
2K
Open
MX$12.85
High
MX$13.10
Low
MX$12.76
Mkt. cap
13.04B
Avg. vol.
3.90M
Volume
4.31M
Dividend
5.74%
Quarterly dividend
MX$0.19
Ex-dividend date
Sep 29, 2026
P/E ratio
7.85
52-wk high
MX$19.48
52-wk low
MX$12.22
EPS
MX$1.66
Shares outstanding
1.00B
No. of employees
2K
News stories
From web sources and news partners
Profile
Genomma Lab Internacional or simply Genomma Lab is a Mexican company, founded in 1996, dedicated to the commercialization of OTC medications and dermocosmetic products. It is part of the Índice de Precios y Cotizaciones, the main stock index of the Mexican Stock Exchange. It is one of the leading pharmaceutical companies in the country. Genomma Lab Internacional, led by its owner Rodrigo Alonso Herrera Aspra, recorded net sales of 9,799.7 million Mexican pesos, equivalent to 756.0 million USD in 2012, achieving a 21.6% growth compared to 2011. Currently, Genomma Lab operates in 15 countries outside Mexico and has achieved success by replicating its business model. Wikipedia
About Genomma Lab Internacional SAB de CV
CEOJorge Luis Brake Valderrama
Employees1.66K
Founded1996
Headquarters-
SectorPharmaceutical industry
Websitegenommalab.com
Previous reportsAll values in MXN
Loading Previous Earnings...
Revenue
Net income
All values in MXN
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.44B
4.02B
4.19B
4.40B
Cost of goods sold
1.61B
1.57B
1.53B
1.56B
Cost of revenue
1.61B
1.57B
1.53B
1.56B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.93B
1.59B
1.78B
1.97B
Operating expense
1.87B
1.64B
1.78B
1.96B
Total operating expenses
3.47B
3.21B
3.32B
3.52B
Operating income
967.77M
805.60M
874.42M
877.20M
Other non operating income
-75.50M
-62.38M
-107.62M
-100.66M
EBT including unusual items
607.56M
568.19M
644.10M
534.73M
EBT excluding unusual items
607.56M
573.06M
644.10M
534.73M
Income tax expense
173.49M
241.94M
149.46M
160.24M
Effective tax rate
28.56%
42.58%
23.20%
29.97%
Other operating expenses
-62.06M
55.69M
-1.44M
-4.17M
Net income
434.07M
326.25M
494.65M
374.49M
Net profit margin
9.77%
8.12%
11.80%
8.52%
Earnings per share
0.63
0.32
0.49
0.37
Interest and investment income
29.60M
23.01M
35.27M
28.54M
Interest expense
-191.65M
-190.68M
-177.79M
-176.65M
Net interest expenses
-162.04M
-167.67M
-142.52M
-148.12M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.06B
900.41M
965.13M
967.58M
Gain or loss from assets sale
57.00K
2.23M
-
-1.19M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps